Excision BioTherapeutics is a biopharmaceutical company based in San Francisco focused on developing gene therapies against HIV infection.
The company has a single, CRISPR–Cas9 based therapy, EBT-101, under investigation. Initial investigation into the therapy was conducted by the lab of Kamel Khalili, a professor at Temple University. In July 2023 the US Food and Drug Administration granted EBT-101 fast-track status. From Wikipedia
